Total Funding
26
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
- David Epstein: Chairman Of The BoardPast Role: Seagen, Chief Executive Officer & Director
- Heidy King-Jones: Senior Vice President, General Counsel & Corporate Secretary
About the Company
Axcella is a clinical-stage biotechnology company that treats complex diseases using endogenous metabolic modulator (EMM) compositions. They combine biological pathways with developments in systems biology and machine learning. Their proprietary platform is clinically validated across several indication areas, with clinical-stage candidates in
muscle, neurodegenerative, and liver conditions.
